PET/CT for the Opportunistic Screening of Osteoporosis and Fractures in Cancer Patients

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM Current Osteoporosis Reports Pub Date : 2024-09-14 DOI:10.1007/s11914-024-00887-x

Peter Sang Uk Park, Thomas J. Werner, Abass Alavi

{"title":"PET/CT for the Opportunistic Screening of Osteoporosis and Fractures in Cancer Patients","authors":"Peter Sang Uk Park, Thomas J. Werner, Abass Alavi","doi":"10.1007/s11914-024-00887-x","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>In this review, we outline the different etiologies of osteoporosis in the oncologic setting and describe the basis for using PET/CT as screening tool for osteoporosis with a focus on the radiotracers [<sup>18</sup>F]FDG and [<sup>18</sup>F]NaF.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Osteoporosis is a condition commonly affecting cancer patients due to their age, cancer-specific treatment agents, and effects of cancer. In terms of the unifying mechanism, decreased ratio of osteoblast-bone formation to osteoclast-bone resorption is responsible for causing osteoporosis. PET/CT, a crucial metabolic imaging modality in the oncologic imaging, could be a useful tool for the opportunistic screening of osteoporosis.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>There are two approaches with which osteoporosis could be identified with PET/CT—using either the (1) CT- based or (2) PET- based approaches. While the CT-based approach has been used with [<sup>18</sup>F]FDG PET/CT, both CT- and PET-based approaches can be employed with [<sup>18</sup>F]NaF-PET/CT as [<sup>18</sup>F]NaF is a radiotracer specific for osteoblast activity.</p>","PeriodicalId":11080,"journal":{"name":"Current Osteoporosis Reports","volume":"166 1","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Osteoporosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11914-024-00887-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of Review

In this review, we outline the different etiologies of osteoporosis in the oncologic setting and describe the basis for using PET/CT as screening tool for osteoporosis with a focus on the radiotracers [¹⁸F]FDG and [¹⁸F]NaF.

Recent Findings

Osteoporosis is a condition commonly affecting cancer patients due to their age, cancer-specific treatment agents, and effects of cancer. In terms of the unifying mechanism, decreased ratio of osteoblast-bone formation to osteoclast-bone resorption is responsible for causing osteoporosis. PET/CT, a crucial metabolic imaging modality in the oncologic imaging, could be a useful tool for the opportunistic screening of osteoporosis.

Summary

There are two approaches with which osteoporosis could be identified with PET/CT—using either the (1) CT- based or (2) PET- based approaches. While the CT-based approach has been used with [¹⁸F]FDG PET/CT, both CT- and PET-based approaches can be employed with [¹⁸F]NaF-PET/CT as [¹⁸F]NaF is a radiotracer specific for osteoblast activity.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

PET/CT 用于癌症患者骨质疏松症和骨折的机会性筛查

综述目的在这篇综述中，我们概述了肿瘤骨质疏松症的不同病因，并描述了使用 PET/CT 作为骨质疏松症筛查工具的基础，重点是放射性同位素 [18F]FDG 和 [18F]NaF。从统一的机制来看，成骨细胞-骨形成与破骨细胞-骨吸收的比例下降是导致骨质疏松症的原因。PET/CT 是肿瘤成像中一种重要的代谢成像方式，可作为骨质疏松症的机会性筛查的有用工具。摘要利用 PET/CT 鉴别骨质疏松症有两种方法--使用（1）基于 CT 的方法或（2）基于 PET 的方法。基于 CT 的方法已被用于[18F]FDG PET/CT，而基于 CT 和 PET 的方法均可用于[18F]NaF-PET/CT，因为[18F]NaF 是一种针对成骨细胞活动的放射性示踪剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Osteoporosis Reports Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

8.80

自引率

2.30%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of osteoporosis. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as current and future therapeutics, epidemiology and pathophysiology, and evaluation and management. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.